Serina Therapeutics Inc - Understand $ser stock

$SER Market Cap: $44.46 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$126.0K

TTM

Gross Margin

98.21%

TTM

Net Earnings

-$6.279M

TTM

Current Assets

$5.423M

Q3 2024

Current Liabilities

$13.51M

Q3 2024

Current Ratio

40.13%

Q3 2024

Total Assets

$7.435M

Q3 2024

Total Liabilities

$21.26M

Q3 2024

Book Value

-$13.83M

Q3 2024

Cash

$3.185M

Q3 2024

P/E

-7.081

Nov 13, 2024 EST

Free Cash Flow

-$9.623M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$142.0K	$34.00K	$144.0K	$361.0K	$1.728M	$1.396M	$1.404M	$1.666M
YoY Change	317.65%	-76.39%	-60.11%	-79.11%	23.78%	-0.57%	-15.73%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$142.0K	$34.00K	$144.0K	$361.0K	$1.728M	$1.396M	$1.404M	$1.666M
Cost Of Revenue	$40.00K	$13.00K	$19.00K	$26.00K	$244.0K	$364.0K	$168.0K	$304.0K
Gross Profit	$102.0K	$21.00K	$125.0K	$335.0K	$1.484M	$1.032M	$1.236M	$1.362M
Gross Profit Margin	71.83%	61.76%	86.81%	92.8%	85.88%	73.93%	88.03%	81.75%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$9.328M	$5.971M	$6.708M	$6.721M	$8.139M	$5.647M	$3.869M	$5.622M
YoY Change	56.22%	-10.99%	-0.19%	-17.42%	44.13%	45.96%	-31.18%
% of Gross Profit	9145.1%	28433.33%	5366.4%	2006.27%	548.45%	547.19%	313.03%	412.78%
Research & Development	$734.0K	$1.025M	$1.325M	$3.582M	$5.904M	$6.630M	$5.784M	$8.479M
YoY Change	-28.39%	-22.64%	-63.01%	-39.33%	-10.95%	14.63%	-31.78%
% of Gross Profit	719.61%	4880.95%	1060.0%	1069.25%	397.84%	642.44%	467.96%	622.54%
Depreciation & Amortization	$131.0K	$132.0K	$0.00	$1.258M	$649.0K	$535.0K	$682.0K	$845.0K
YoY Change	-0.76%		-100.0%	93.84%	21.31%	-21.55%	-19.29%
% of Gross Profit	128.43%	628.57%	0.0%	375.52%	43.73%	51.84%	55.18%	62.04%
Operating Expenses	$10.06M	$6.996M	$8.164M	$10.44M	$14.04M	$12.28M	$9.653M	$14.10M
YoY Change	43.83%	-14.31%	-21.76%	-25.69%	14.38%	27.18%	-31.54%
Operating Profit	-$9.887M	-$6.975M	-$8.039M	-$10.10M	-$12.56M	-$11.25M	-$8.417M	-$12.74M
YoY Change	41.75%	-13.24%	-20.41%	-19.58%	11.69%	33.6%	-33.93%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$4.900M	$3.335M	-$1.097M	-$404.0K	$29.00K	$3.331M	-$12.00K	-$4.696M
YoY Change	46.93%	-404.01%	171.53%	-1493.1%	-99.13%	-27858.33%	-99.74%
% of Operating Profit
Other Income/Expense, Net	-$4.924M	-$3.547M	$448.0K	$105.0K	$294.0K	$183.0K	$38.00K	$80.00K
YoY Change	38.82%	-891.74%	326.67%	-64.29%	60.66%	381.58%	-52.5%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	$14.80M	$10.50M	-$8.582M	-$10.40M	-$12.24M	-$7.731M	-$6.637M	-$17.36M
YoY Change	40.95%	-222.35%	-17.47%	-15.01%	58.27%	16.48%	-61.76%
Income Tax				-$150.0K	$148.0K
% Of Pretax Income
Net Earnings	-$14.80M	-$10.46M	-$8.675M	-$10.87M	-$12.15M	-$7.502M	-$6.580M	-$15.49M
YoY Change	41.49%	20.6%	-20.16%	-10.61%	62.01%	14.01%	-57.53%
Net Earnings / Revenue	-10424.65%	-30770.59%	-6024.31%	-3009.7%	-703.36%	-537.39%	-468.66%	-929.89%
Basic Earnings Per Share	-$13.72	-$0.28	-$0.23
Diluted Earnings Per Share	-$13.72	-$0.28	-$229.0K	-$288.4K	-$326.1K	-$214.9K	-$183.6K	-$432.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$345.0K	$645.0K	$584.0K	$527.0K	$2.352M	$6.707M	$7.375M	$259.0K
YoY Change	-46.51%	10.45%	10.82%	-77.59%	-64.93%	-9.06%	2747.49%
Cash & Equivalents	$345.0K	$645.0K	$584.0K	$527.0K	$2.352M	$6.707M	$7.375M	$259.0K
Short-Term Investments
Other Short-Term Assets	$352.0K	$1.804M	$1.625M	$1.430M	$1.339M	$1.015M	$111.0K	$121.0K
YoY Change	-80.49%	11.02%	13.64%	6.8%	31.92%	814.41%	-8.26%
Inventory
Prepaid Expenses
Receivables	$57.00K	$4.000K	$25.00K	$326.0K	$363.0K	$131.0K	$107.0K	$308.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$754.0K	$2.453M	$2.234M	$2.283M	$4.054M	$7.853M	$7.593M	$688.0K
YoY Change	-69.26%	9.8%	-2.15%	-43.69%	-48.38%	3.42%	1003.63%
Property, Plant & Equipment				$0.00	$1.126M	$90.00K	$129.0K	$195.0K
YoY Change				-100.0%	1151.11%	-30.23%	-33.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K	$50.00K	$111.0K	$19.00K	$35.00K	$39.00K
YoY Change	0.0%	0.0%	0.0%	-54.95%	484.21%	-45.71%	-10.26%
Total Long-Term Assets	$11.21M	$788.0K	$920.0K	$1.642M	$3.388M	$2.818M	$2.038M	$2.535M
YoY Change	1322.72%	-14.35%	-43.97%	-51.53%	20.23%	38.27%	-19.61%
Total Assets	$11.97M	$3.241M	$3.154M	$3.925M	$7.442M	$10.67M	$9.631M	$3.223M
YoY Change
Accounts Payable	$1.413M	$568.0K	$193.0K	$761.0K	$420.0K	$150.0K	$75.00K	$261.0K
YoY Change	148.77%	194.3%	-74.64%	81.19%	180.0%	100.0%	-71.26%
Accrued Expenses	$763.0K	$466.0K	$578.0K	$895.0K	$1.590M	$1.266M	$693.0K	$1.826M
YoY Change	63.73%	-19.38%	-35.42%	-43.71%	25.59%	82.68%	-62.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$436.0K	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$3.672M	$7.646M	$7.140M	$1.960M
YoY Change	-51.97%	7.09%	264.29%
Total Short-Term Liabilities	$5.914M	$10.08M	$8.967M	$5.357M	$3.297M	$2.440M	$1.312M	$25.60M
YoY Change	-41.32%	12.39%	67.39%	62.48%	35.12%	85.98%	-94.87%
Long-Term Debt	$693.0K	$10.48M	$6.062M	$3.900M	$1.528M	$0.00	$0.00	$0.00
YoY Change	-93.39%	72.85%	55.44%	155.24%
Other Long-Term Liabilities			$0.00	$64.00K
YoY Change			-100.0%
Total Long-Term Liabilities	$693.0K	$10.48M	$6.062M	$3.964M	$1.528M	$0.00	$0.00	$0.00
YoY Change	-93.39%	72.85%	52.93%	159.42%
Total Liabilities	$6.496M	$20.45M	$14.99M	$9.041M	$5.224M	$3.224M	$2.351M	$26.64M
YoY Change	-68.24%	36.48%	65.76%	73.07%	62.03%	37.13%	-91.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	1.079K shares	37.95M shares	37.89M shares
Diluted Shares Outstanding	1.079K shares	1.079K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $44.46 Million

About Serina Therapeutics Inc

Serina Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Alameda, California and currently employs 4 full-time employees. The company went IPO on 2018-11-29. Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The firm is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The firm is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The firm intends to advance SER 252 into Phase I clinical trials.

Industry: Pharmaceutical Preparations Peers: REGENERX BIOPHARMACEUTICALS INC BIO-PATH HOLDINGS, INC. eFFECTOR Therapeutics Inc Forte Biosciences Inc Vincerx Pharma Inc Oncotelic Therapeutics Inc Oncorus, Inc. Regulus Therapeutics Inc Tonix Pharmaceuticals Holding Corp